GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AC Immune ACIU · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.95

-8.45%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

AC Immune — daily ACIU Delayed
Market value
$195.8m
Last close × shares
Volume
298.4k
Shares, 20 Nov 2026

About AC Immune

Its shares trade under the ticker ACIU. It has been listed since 23 September 2016. In the fiscal year to 31 December 2025, it reported revenue of CHF 3.6m and a net loss of CHF 70.4m. At that date it held total assets of CHF 154.4m and shareholders' equity of CHF 44.9m.

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Figures and description from our data supplier, not checked against the company's own report.

More about AC Immune →

Latest on AC Immune

Our reporting

Next results

12 Mar 2027

Due on 12 Mar 2027. Analysts expect earnings of -0.16 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is AC Immune's ticker?

AC Immune trades as ACIU on its US listing, under ISIN CH0329023102.

What was AC Immune's last closing price?

1.95 on 20 Nov 2026. The figure is in USD and is never converted.

When does AC Immune next report results?

Results are expected on 18 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.